WO1998029152A1 - Injection device - Google Patents

Injection device Download PDF

Info

Publication number
WO1998029152A1
WO1998029152A1 PCT/EP1997/007262 EP9707262W WO9829152A1 WO 1998029152 A1 WO1998029152 A1 WO 1998029152A1 EP 9707262 W EP9707262 W EP 9707262W WO 9829152 A1 WO9829152 A1 WO 9829152A1
Authority
WO
WIPO (PCT)
Prior art keywords
housing
plunger
needle
sleeve
septum
Prior art date
Application number
PCT/EP1997/007262
Other languages
French (fr)
Inventor
Roland Cherif-Cheikh
Original Assignee
Delab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delab filed Critical Delab
Priority to EP97953913A priority Critical patent/EP0954346B1/en
Priority to AT97953913T priority patent/ATE281198T1/en
Priority to DE69731482T priority patent/DE69731482T2/en
Priority to AU57635/98A priority patent/AU5763598A/en
Publication of WO1998029152A1 publication Critical patent/WO1998029152A1/en
Priority to HK01022810A priority patent/HK1024190A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321Means for protection against accidental injuries by used needles
    • A61M5/3243Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/3257Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/32Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321Means for protection against accidental injuries by used needles
    • A61M5/3243Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A61M2005/3265Degree of extension of sleeve to its needle covering position is progressively established by the degree of piston insertion into the syringe barrel

Definitions

  • the invention relates to a device for the parenteral administration through a needle of liquid or semi-solid drug compositions wherein the needle is protected before and after the injection.
  • parenteral introduction of pharmaceutically active compounds is preferred over oral dosage for many indications, e.g., where the drug to be administered would partially or totally degrade in the gastrointestinal tract, or where there is need for a rapid biological response .
  • the need for extemporaneous preparation of such parenteral compositions is eliminated, or simplified, by the use of pre-filled administration devices in which the liquid to be injected is pre-loaded into the device (e.g., a pre-loaded syringe) .
  • pre-loaded devices have a number of drawbacks, including the inability to preserve the asepsis or sterility of the needle, as well as the general danger of using an exposed needle. To eliminate these drawbacks, it is necessary to avoid the direct exposure of the needle with the environment both prior to and following injection.
  • the invention features a comparatively inexpensive injection device with a needle for parenteral injection of liquid or semi-solid drug compositions into a subject, e.g., a mammal such as a human, wherein the needle is protected both before and after the injection.
  • the invention features an injection device including a housing, the housing having proximal and distal ends and designed to contain a liquid or semi- solid drug composition; a hollow needle, the needle affixed to the distal end of the housing and extending longitudinally within the housing; a plunger, the plunger arranged to slide within the proximal end of the housing; and a hollow sleeve, the hollow sleeve arranged to cover the needle prior to injection and arranged to retract into the housing during injection; wherein the device is designed such that when the sleeve is pressed against the subject, the sleeve retracts into the housing thereby allowing the needle to penetrate the subject, and when the plunger is forced further into the housing, the drug composition is forced from the housing through the needle and into the subject.
  • the device is further designed such that when the drug composition is forced from the housing, the plunger forces the sleeve out of the housing to cover the needle.
  • the housing contains the liquid or semi-solid drug composition.
  • the device further comprises a septum plunger, the septum plunger slidably arranged within the housing between the plunger and the distal end of the housing.
  • the device is further designed such that when the drug composition is forced from the housing, the plunger forces the septum plunger into the sleeve, and the septum plunger forces the sleeve out of the housing to cover the needle.
  • the housing contains the liquid or semi -solid drug composition between the plunger and the septum plunger.
  • the housing contains a liquid and a dry drug composition, where the device is designed to combine the liquid and the dry drug composition prior to injection.
  • the device can further include a releasable lock to inhibit the movement of the plunger into the housing.
  • the device can also include a removable cap which covers the sleeve.
  • the proximal end of the housing may have a flange and the plunger may also have a flange.
  • FIG. 1 is a partial cross-sectional view of an injection device prior to use.
  • Fig. 2 is a partial cross-sectional view of the injection device of Fig. 1 during use.
  • Fig. 3 is a partial cross-sectional view of the device with the needle injected into a subject.
  • Fig. 4 is a partial cross-sectional view of the injection device being withdrawn from the subject with a drug composition remaining in the subject.
  • Fig. 5 is a partial cross-sectional view of the injection device following complete withdrawal of the needle from the subject.
  • Fig. 6 is a cross-section of the injection device through line 6-6 in Fig. 1.
  • Fig. 7 is a view of the sleeve of the injection device . Detailed Description It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific
  • Fig. 1 shows injection device 1 including housing 10, having a proximal end and a distal end 14a, 14b.
  • the distal end of housing 10 has two holes 40a and 40b o partially separating the two parts 14a and 14b of the distal end (as best seen in Fig. 6) .
  • Needle 12 is attached to part 14a of the distal end.
  • the housing 10 can be made from a rigid material such as glass, plastic, or metal.
  • the needle 12 is hollow and double-ended, s wherein its distal end, remaining outside housing 10, has a point capable of piercing the skin of a subject, and its proximal end, remaining within housing 10, is capable of piercing septum plunger 16.
  • On the proximal end of housing 10 is a flange 28 to assist in removal of device 0 1 from the subject following injection.
  • Sleeve 22 surrounds needle 12 so that needle 12 is not fully exposed to the environment until used.
  • Sleeve 22 has longitudinal slots 45a and 45b along its length (see Fig. 7; slot 45b is on the back of the sleeve
  • connecting members 42a and 42b are joined by radially extending connecting members 42a and 42b (see Fig. 6) .
  • Connecting members 42a and 42b respectively, slide through slots 45a and 45b in sleeve 22, while sleeve 22 slides through holes 40a and
  • Sleeve 22 can be made of suitably rigid material, such as metal, glass, or plastic.
  • Seal 24 covers the opening 23 of sleeve 22 to maintain the sterility of needle 12 and prevent sleeve 22 from unintentionally retracting into housing 10 through holes
  • Seal 24 can be made of a thin material, such as plastic or wax, which is easily penetrated by needle 12 during injection.
  • a similar seal can also cover slots 45a and 45b in sleeve 22, to further protect the sterility of needle 12.
  • Septum plunger 16 contained within housing 10 includes a bore 26, in which needle 12 rests prior to subsequently piercing septum plunger 16.
  • a liquid or semi-solid composition 20 is isolated in housing 10 between the septum plunger 16 and the plunger tip 30, attached to plunger 29.
  • Septum plunger 16 and plunger tip 30 may be made of non-rigid, solid material such as rubber, which allows septum plunger 16 and plunger tip 30 to slide within housing 10 but still maintain sufficient friction with the inner sides of housing 10 to seal composition 20 within housing 10.
  • the proximal end of plunger 29 has a thumb flange 18 to assist in the depression of plunger 29 into housing 10, and the distal end of plunger 29 has a longitudinal bore 27 to receive needle 12 following injection of composition 20 out and through needle 12.
  • Plunger 29 can be made from a rigid material, such as metal or plastic.
  • a removable lock 25 may be placed between flange 18 and flange 28 to inhibit the further depression of plunger 29 into housing 10 after activation of device 1, i.e., after the housing 10 is filled with a drug composition and the proximal end of the needle is pierced through septum plunger 16.
  • a removable cap 21 can also be used to protect both needle 12 and sleeve 22 prior to use. Both cap 21 and lock 25 can be made from suitable rigid material such as plastic, metal, or rubber.
  • Fig. 2 shows device 1 wherein plunger 29 has been pressed into housing 10 to activate device 1 as follows.
  • plunger tip 30, composition 20, and septum plunger 16 are displaced toward the distal end of housing 10.
  • Septum plunger 16 is pierced at bore 26 by needle 12.
  • the proximal end of needle 12 is exposed to composition 20.
  • Device 1 is now in an activated state.
  • Fig. 3 shows device 1 wherein needle 12 has penetrated skin 32 of the subject being treated.
  • sleeve 22 As device 1 is pressed against skin 32, sleeve 22 is retracted into housing 10, through holes 40a and 40b, by the force of pressure against skin 32. Needle 12 passes through sleeve 22 at opening 23. As shown, needle 12 has penetrated through skin 32 into the subcutaneous layer 34.
  • Fig. 4 shows device 1 wherein lock 25 has been removed and plunger 29 has been depressed which moves plunger tip 30 toward septum plunger 16, thereby injecting composition 20 into subcutaneous layer 34 through needle 12.
  • housing 10 is moved away from skin 32 by exerting pressure against the lower part of the flange 28 while simultaneously exerting opposing pressure on flange 18 of plunger 29.
  • This relative movement of the plunger 29 and housing 10 causes plunger tip 30 to force septum plunger 16 against sleeve 22 as both plunger tip 30 and septum plunger 16 slide toward parts 14a and 14b of the distal end of housing 10, which in turn forces sleeve 22 out of housing 10 through holes 40a and 40b.
  • FIG. 5 shows needle 12 fully withdrawn from skin 32 and sleeve 22 fully covering needle 12. Composition 20 remains in the subcutaneous layer of the patient. As can also be seen in Fig. 5, the proximal end of needle 12 has been pushed through septum plunger 16 and plunger tip
  • FIG. 6 is a cross-sectional view of Fig. 1 at 6-6.
  • Fig. 6 shows holes 40a and 40b in housing 10.
  • Radially extending connecting members 42a and 42b extend through slots 45a and 45b, respectively, to connect parts 14a and 14b of the distal end.
  • Needle 12 is fixed to central part 14a of the distal end, and sleeve 22 can slide through holes 40a and 40b.
  • Fig. 7 shows an isolated sleeve 22 having slots 45a and 45b (45b is not shown but positioned directly opposite to slot 45a on the other side of sleeve 22) and opening 23.
  • Composition 20 is a liquid or a viscous semi-solid composition containing a drug.
  • the drug of composition 20 can be any drug capable of being parenterally o administered as a liquid or a semi -solid.
  • the drug can be a vaccine, a peptide, a protein, or a small chemical entity.
  • suitable drugs include insulin and heparin.
  • the 5 liquid and the dry drug can be stored in separate chambers within housing 10. The device can be designed such that the liquid and the dry drug are combined together just prior to injection.
  • the chamber created between septum 0 plunger 16 and plunger tip 30 (e.g., in Fig. 1) in housing 10 can be separated into two separate parts by a fixed wall or film that can be punctured, e.g., by pressure of the plunger 29 on the plunger tip 30, or a puncturing means.
  • the two parts of the 5 chamber can be separated by a moving wall or septum.
  • the top or proximal part of the chamber above the moving septum contains the liquid portion of the composition
  • the distal part of the chamber contains the solid, e.g., powder, portion of the composition.
  • the housing is designed with a liquid bypass (e.g., a bulge or passage in the housing wall) in a location that initially prevents passage of liquid from one part of the chamber to the other, but when the moving septum reaches a specific location, the bypass allows the liquid to pass from the top part of the chamber into the lower or proximal part of the chamber on the other side of the moving septum.
  • a liquid bypass e.g., a bulge or passage in the housing wall
  • the device of the invention can be stored in a conventional blister pack prior to use .

Abstract

The invention features an injection device for injecting a liquid or semi-solid composition into a subject.

Description

INJECTION DEVICE Background of the Invention
The invention relates to a device for the parenteral administration through a needle of liquid or semi-solid drug compositions wherein the needle is protected before and after the injection.
The parenteral introduction of pharmaceutically active compounds is preferred over oral dosage for many indications, e.g., where the drug to be administered would partially or totally degrade in the gastrointestinal tract, or where there is need for a rapid biological response . The need for extemporaneous preparation of such parenteral compositions is eliminated, or simplified, by the use of pre-filled administration devices in which the liquid to be injected is pre-loaded into the device (e.g., a pre-loaded syringe) . Such pre-loaded devices, however, have a number of drawbacks, including the inability to preserve the asepsis or sterility of the needle, as well as the general danger of using an exposed needle. To eliminate these drawbacks, it is necessary to avoid the direct exposure of the needle with the environment both prior to and following injection.
Summary of the Invention
The invention features a comparatively inexpensive injection device with a needle for parenteral injection of liquid or semi-solid drug compositions into a subject, e.g., a mammal such as a human, wherein the needle is protected both before and after the injection.
In general, the invention features an injection device including a housing, the housing having proximal and distal ends and designed to contain a liquid or semi- solid drug composition; a hollow needle, the needle affixed to the distal end of the housing and extending longitudinally within the housing; a plunger, the plunger arranged to slide within the proximal end of the housing; and a hollow sleeve, the hollow sleeve arranged to cover the needle prior to injection and arranged to retract into the housing during injection; wherein the device is designed such that when the sleeve is pressed against the subject, the sleeve retracts into the housing thereby allowing the needle to penetrate the subject, and when the plunger is forced further into the housing, the drug composition is forced from the housing through the needle and into the subject.
In one embodiment, the device is further designed such that when the drug composition is forced from the housing, the plunger forces the sleeve out of the housing to cover the needle. In a further embodiment, the housing contains the liquid or semi-solid drug composition.
In another embodiment, the device further comprises a septum plunger, the septum plunger slidably arranged within the housing between the plunger and the distal end of the housing. In a further embodiment, the device is further designed such that when the drug composition is forced from the housing, the plunger forces the septum plunger into the sleeve, and the septum plunger forces the sleeve out of the housing to cover the needle. In still a further embodiment, the housing contains the liquid or semi -solid drug composition between the plunger and the septum plunger.
In still another embodiment, the housing contains a liquid and a dry drug composition, where the device is designed to combine the liquid and the dry drug composition prior to injection.
The device can further include a releasable lock to inhibit the movement of the plunger into the housing. The device can also include a removable cap which covers the sleeve. The proximal end of the housing may have a flange and the plunger may also have a flange. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
Brief Description of the Drawings Fig. 1 is a partial cross-sectional view of an injection device prior to use.
Fig. 2 is a partial cross-sectional view of the injection device of Fig. 1 during use.
Fig. 3 is a partial cross-sectional view of the device with the needle injected into a subject. Fig. 4 is a partial cross-sectional view of the injection device being withdrawn from the subject with a drug composition remaining in the subject.
Fig. 5 is a partial cross-sectional view of the injection device following complete withdrawal of the needle from the subject.
Fig. 6 is a cross-section of the injection device through line 6-6 in Fig. 1.
Fig. 7 is a view of the sleeve of the injection device . Detailed Description It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific
5 embodiments are, therefore, to be construed as merely illustrative, and not limiting.
Fig. 1 shows injection device 1 including housing 10, having a proximal end and a distal end 14a, 14b. The distal end of housing 10 has two holes 40a and 40b o partially separating the two parts 14a and 14b of the distal end (as best seen in Fig. 6) . Needle 12 is attached to part 14a of the distal end. The housing 10 can be made from a rigid material such as glass, plastic, or metal. The needle 12 is hollow and double-ended, s wherein its distal end, remaining outside housing 10, has a point capable of piercing the skin of a subject, and its proximal end, remaining within housing 10, is capable of piercing septum plunger 16. On the proximal end of housing 10 is a flange 28 to assist in removal of device 0 1 from the subject following injection.
An sleeve 22 surrounds needle 12 so that needle 12 is not fully exposed to the environment until used. Sleeve 22 has longitudinal slots 45a and 45b along its length (see Fig. 7; slot 45b is on the back of the sleeve
25 and is thus not shown) . The two parts 14a and 14b of the distal end are joined by radially extending connecting members 42a and 42b (see Fig. 6) . Connecting members 42a and 42b, respectively, slide through slots 45a and 45b in sleeve 22, while sleeve 22 slides through holes 40a and
30 40b in housing 10. Sleeve 22 can be made of suitably rigid material, such as metal, glass, or plastic. Seal 24 covers the opening 23 of sleeve 22 to maintain the sterility of needle 12 and prevent sleeve 22 from unintentionally retracting into housing 10 through holes
35 40a and 40b prior to injection. Seal 24 can be made of a thin material, such as plastic or wax, which is easily penetrated by needle 12 during injection. A similar seal can also cover slots 45a and 45b in sleeve 22, to further protect the sterility of needle 12.
Septum plunger 16, contained within housing 10, includes a bore 26, in which needle 12 rests prior to subsequently piercing septum plunger 16. A liquid or semi-solid composition 20 is isolated in housing 10 between the septum plunger 16 and the plunger tip 30, attached to plunger 29. Septum plunger 16 and plunger tip 30 may be made of non-rigid, solid material such as rubber, which allows septum plunger 16 and plunger tip 30 to slide within housing 10 but still maintain sufficient friction with the inner sides of housing 10 to seal composition 20 within housing 10.
The proximal end of plunger 29 has a thumb flange 18 to assist in the depression of plunger 29 into housing 10, and the distal end of plunger 29 has a longitudinal bore 27 to receive needle 12 following injection of composition 20 out and through needle 12. Plunger 29 can be made from a rigid material, such as metal or plastic. A removable lock 25 may be placed between flange 18 and flange 28 to inhibit the further depression of plunger 29 into housing 10 after activation of device 1, i.e., after the housing 10 is filled with a drug composition and the proximal end of the needle is pierced through septum plunger 16. A removable cap 21 can also be used to protect both needle 12 and sleeve 22 prior to use. Both cap 21 and lock 25 can be made from suitable rigid material such as plastic, metal, or rubber.
Fig. 2 shows device 1 wherein plunger 29 has been pressed into housing 10 to activate device 1 as follows. When plunger 29 is depressed, plunger tip 30, composition 20, and septum plunger 16 are displaced toward the distal end of housing 10. Septum plunger 16 is pierced at bore 26 by needle 12. As a result, the proximal end of needle 12 is exposed to composition 20. Device 1 is now in an activated state. Lock 25, by contacting both flange 18 and flange 28, inhibits the further displacement of composition 20 from housing 10 through needle 12 following activation of device 1, i.e., composition 20 is allowed to fill needle 10, but lock 25 inhibits significant release of composition 20 through needle 10. Fig. 3 shows device 1 wherein needle 12 has penetrated skin 32 of the subject being treated. As device 1 is pressed against skin 32, sleeve 22 is retracted into housing 10, through holes 40a and 40b, by the force of pressure against skin 32. Needle 12 passes through sleeve 22 at opening 23. As shown, needle 12 has penetrated through skin 32 into the subcutaneous layer 34.
Fig. 4 shows device 1 wherein lock 25 has been removed and plunger 29 has been depressed which moves plunger tip 30 toward septum plunger 16, thereby injecting composition 20 into subcutaneous layer 34 through needle 12. Once composition 20 has been injected and plunger tip 30 rests against septum plunger 16, housing 10 is moved away from skin 32 by exerting pressure against the lower part of the flange 28 while simultaneously exerting opposing pressure on flange 18 of plunger 29. This relative movement of the plunger 29 and housing 10 causes plunger tip 30 to force septum plunger 16 against sleeve 22 as both plunger tip 30 and septum plunger 16 slide toward parts 14a and 14b of the distal end of housing 10, which in turn forces sleeve 22 out of housing 10 through holes 40a and 40b. As plunger tip 30 and septum plunger 16 are moved toward distal end of housing 10, needle 12 penetrates septum plunger 16, plunger tip 30, and enters bore 27 in plunger 29. Fig. 5 shows needle 12 fully withdrawn from skin 32 and sleeve 22 fully covering needle 12. Composition 20 remains in the subcutaneous layer of the patient. As can also be seen in Fig. 5, the proximal end of needle 12 has been pushed through septum plunger 16 and plunger tip
30 and remains in bore 27 of plunger 29. Fig. 6 is a cross-sectional view of Fig. 1 at 6-6. Fig. 6 shows holes 40a and 40b in housing 10. Radially extending connecting members 42a and 42b extend through slots 45a and 45b, respectively, to connect parts 14a and 14b of the distal end. Needle 12 is fixed to central part 14a of the distal end, and sleeve 22 can slide through holes 40a and 40b. Fig. 7 shows an isolated sleeve 22 having slots 45a and 45b (45b is not shown but positioned directly opposite to slot 45a on the other side of sleeve 22) and opening 23. Radially extending s connecting members 42a and 42b, respectively, slide through slots 45a and 45b.
Composition 20 is a liquid or a viscous semi-solid composition containing a drug. The drug of composition 20 can be any drug capable of being parenterally o administered as a liquid or a semi -solid. For example, the drug can be a vaccine, a peptide, a protein, or a small chemical entity. Examples of suitable drugs include insulin and heparin. For drugs which are not stable in liquids over an extended period of time, the 5 liquid and the dry drug can be stored in separate chambers within housing 10. The device can be designed such that the liquid and the dry drug are combined together just prior to injection.
For example, the chamber created between septum 0 plunger 16 and plunger tip 30 (e.g., in Fig. 1) in housing 10 can be separated into two separate parts by a fixed wall or film that can be punctured, e.g., by pressure of the plunger 29 on the plunger tip 30, or a puncturing means. Alternatively, the two parts of the 5 chamber can be separated by a moving wall or septum. In this case, the top or proximal part of the chamber above the moving septum contains the liquid portion of the composition, and the distal part of the chamber contains the solid, e.g., powder, portion of the composition. When plunger 29 is pushed down, it applies pressure to the plunger tip 30, which applies pressure to the liquid portion of the composition. This, in turn, applies pressure on the moving septum, causing it to move in a distal direction. The housing is designed with a liquid bypass (e.g., a bulge or passage in the housing wall) in a location that initially prevents passage of liquid from one part of the chamber to the other, but when the moving septum reaches a specific location, the bypass allows the liquid to pass from the top part of the chamber into the lower or proximal part of the chamber on the other side of the moving septum.
To maintain sterility, the device of the invention can be stored in a conventional blister pack prior to use .
OTHER EMBODIMENTS It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.

Claims

What is claimed is:
1. An injection device for injecting a liquid or semi-solid composition into a subject, the device comprising: a hollow housing having a proximal end and distal end, said housing being configured to contain a liquid or semi-solid composition; a hollow needle, said needle affixed to the distal end of the housing and extending longitudinally within said housing; a plunger arranged to slide within the proximal end of the housing; and a hollow sleeve slidably connected to the distal end of the housing and arranged to cover the needle prior to injection and to retract into the housing during injection; wherein the device is configured such that when the sleeve is pressed against the subject, the sleeve retracts into the housing thereby allowing the needle to penetrate into the subject, and when the plunger is pushed into the housing, the composition is pushed from the housing through the needle and into the subject.
2. A device of claim 1, wherein the device further comprises a septum plunger slidably arranged within the housing between the plunger and the distal end of the housing.
3. An injection device of claim 1, wherein the device is further configured such that when the composition is pushed out of the housing, the plunger moves the sleeve out of the housing to cover the needle.
4. An injection device of claim 2, wherein the device is further configured such that when the composition is pushed out of the housing, the plunger moves the septum plunger into the sleeve, and the septum plunger pushes the sleeve out of the housing to cover the needle .
5. A device of claim 1, wherein the housing contains the liquid or semi-solid composition.
6. A device of claim 3, wherein the housing contains the liquid or semi-solid composition.
7. A device of claim 2, wherein the housing contains the liquid or semi -solid composition between the plunger and the septum plunger.
8. A device of claim 4, wherein the housing contains the liquid or semi-solid composition between the plunger and the septum plunger.
9. A device of claim 1, wherein the device further comprises a releasable lock to inhibit movement of the plunger into the housing.
10. A device of claim 2, wherein the device further comprises a releasable lock to inhibit the movement of the plunger into the housing.
11. A device of claim 1, wherein the device comprises a removable cap which covers the sleeve.
12. A device of claim 2, wherein the device comprises a removable cap which covers the sleeve.
13. A device of claim 1, wherein the proximal end of the housing comprises a flange.
14. A device of claim 2, wherein the proximal end of the housing comprises a flange.
15. A device of claim 1, wherein the plunger comprises a flange.
16. A device of claim 2, wherein the plunger comprises a flange.
PCT/EP1997/007262 1996-12-31 1997-12-23 Injection device WO1998029152A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97953913A EP0954346B1 (en) 1996-12-31 1997-12-23 Injection device
AT97953913T ATE281198T1 (en) 1996-12-31 1997-12-23 INJECTION DEVICE
DE69731482T DE69731482T2 (en) 1996-12-31 1997-12-23 INJECTION DEVICE
AU57635/98A AU5763598A (en) 1996-12-31 1997-12-23 Injection device
HK01022810A HK1024190A1 (en) 1996-12-31 2000-05-10 Injection device.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/777,634 1996-12-31
US08/777,634 US5776107A (en) 1996-12-31 1996-12-31 Injection device

Publications (1)

Publication Number Publication Date
WO1998029152A1 true WO1998029152A1 (en) 1998-07-09

Family

ID=25110799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/007262 WO1998029152A1 (en) 1996-12-31 1997-12-23 Injection device

Country Status (10)

Country Link
US (2) US5776107A (en)
EP (1) EP0954346B1 (en)
AT (1) ATE281198T1 (en)
AU (1) AU5763598A (en)
DE (1) DE69731482T2 (en)
DK (1) DK0954346T3 (en)
ES (1) ES2230628T3 (en)
HK (1) HK1024190A1 (en)
PT (1) PT954346E (en)
WO (1) WO1998029152A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096488A1 (en) * 2001-04-10 2002-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Safety injection device for a liquid or semi-solid composition
US7445612B2 (en) 1996-12-31 2008-11-04 Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S. Safety injection device for a liquid or semi-solid composition
JP2009045501A (en) * 1998-09-18 2009-03-05 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) Syringe for injecting pasty or semi-solid formulation
JP4771957B2 (en) * 2003-11-03 2011-09-14 ベクトン・ディキンソン・アンド・カンパニー Safety device for syringe

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776107A (en) * 1996-12-31 1998-07-07 Delab Injection device
US6004296A (en) 1997-09-30 1999-12-21 Becton Dickinson France, S.A. Lockable safety shield assembly for a prefillable syringe
US6319233B1 (en) 1998-04-17 2001-11-20 Becton, Dickinson And Company Safety shield system for prefilled syringes
US6679864B2 (en) 1998-04-17 2004-01-20 Becton Dickinson And Company Safety shield system for prefilled syringes
US6719730B2 (en) 1998-04-17 2004-04-13 Becton, Dickinson And Company Safety shield system for prefilled syringes
WO2000062759A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
DE19947998B4 (en) * 1999-10-06 2004-04-15 Bünder Glas GmbH Hypodermic syringe with needle guard
US6629958B1 (en) 2000-06-07 2003-10-07 Ronald P. Spinello Leak sealing needle
WO2002005744A1 (en) * 2000-07-14 2002-01-24 Novo Nordisk A/S Method of moulding a pharmaceutical composition in a packaging material
US20040096463A1 (en) * 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
WO2002074336A2 (en) * 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
DE10293048T1 (en) * 2001-04-27 2003-07-31 Glaxosmithkline Biolog Sa New vaccine
GB0118419D0 (en) * 2001-07-28 2001-09-19 Owen Mumford Ltd Improvements relating to injection devices
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
US7449012B2 (en) * 2004-08-06 2008-11-11 Meridian Medical Technologies, Inc. Automatic injector
US8048035B2 (en) * 2004-08-06 2011-11-01 Meridian Medical Technologies, Inc. Automatic injector with needle cover
US8057431B2 (en) 2006-12-21 2011-11-15 B. Braun Melsungen Ag Hinged cap for needle device
CN107106280A (en) 2014-12-23 2017-08-29 奥特梅德私人有限公司 Conveying equipment, system and associated method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009022A1 (en) * 1993-09-29 1995-04-06 Alan Christopher Allison Improvements in safety needle and syringe
FR2736553A1 (en) * 1995-07-12 1997-01-17 Soc Et Et D Applic Tech Sedat INJECTION SYRINGE, IN PARTICULAR LIQUID MEDICAL PRODUCTS, WITH MOBILE NEEDLE PROTECTOR
FR2741268A1 (en) * 1995-11-21 1997-05-23 Turtaut Patrick Pre-filled syringe with protected needle of variable length

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1168371A (en) * 1957-01-07 1958-12-08 Veterinary device with automatic reloading for subcutaneous implantation of hormonal or other tablets
US3016895A (en) * 1958-08-01 1962-01-16 Pan American Lab Inc Injector for subcutaneous implantation of solids
US3572335A (en) * 1969-01-10 1971-03-23 Ralph R Robinson Cervical implant method and device
US3884230A (en) * 1973-09-27 1975-05-20 Goldwyn L Wulff Flexible needle and guard device for a hypodermic syringe
US4233975A (en) * 1978-10-04 1980-11-18 Yerman Arthur J Anti-drug abuse single-use syringe
US4359044A (en) * 1979-08-01 1982-11-16 Child Francis W Method for placing implant in udder
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
US4820267A (en) * 1985-02-19 1989-04-11 Endocon, Inc. Cartridge injector for pellet medicaments
US4846793A (en) * 1987-03-18 1989-07-11 Endocon, Inc. Injector for implanting multiple pellet medicaments
US4994028A (en) * 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
DE3855054T2 (en) * 1987-05-26 1996-07-18 Sumitomo Pharma Device for the administration of solid preparations
US4850968A (en) * 1987-07-27 1989-07-25 Ar.Ma.S.R.L. Self-blocking hypodermic syringe for once-only use, comprising a needle protection cap
NL8901124A (en) * 1989-05-03 1990-12-03 Nedap Nv Closed implanting instrument - accommodates sterile injection needle and implant before use
NL8902186A (en) * 1989-08-30 1991-03-18 Nedap Nv RECHARGEABLE IMPLANT TOOL WITH AUTOMATIC RELEASE.
US5284479A (en) * 1989-08-30 1994-02-08 N.V. Nederlandsche Apparatenfabriek Nedap Implanter
GB2240718A (en) * 1990-02-09 1991-08-14 Hundon Forge Ltd Implanting device with needle cover
US5098389A (en) * 1990-06-28 1992-03-24 Becton, Dickinson And Company Hypodermic needle assembly
US5151088A (en) * 1991-07-31 1992-09-29 The Board Of Trustees Of The Leland Stanford Junior University Safety needle and syringe assembly
US5250026A (en) * 1992-05-27 1993-10-05 Destron/Idi, Inc. Adjustable precision transponder injector
US5267972A (en) * 1992-07-20 1993-12-07 Anderson Wayne W Hypodermic syringe with needle guard
US5275583A (en) * 1992-10-05 1994-01-04 Lawrence Crainich Trocar assembly with independently acting shield means
US5433711A (en) * 1994-08-01 1995-07-18 Monsanto Company Syringe with cannula-protecting sheath and sealing center rod
US5487733A (en) * 1994-09-20 1996-01-30 Becton, Dickinson And Company Assembly with collapsible sheath and tip guard
US5776107A (en) * 1996-12-31 1998-07-07 Delab Injection device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009022A1 (en) * 1993-09-29 1995-04-06 Alan Christopher Allison Improvements in safety needle and syringe
FR2736553A1 (en) * 1995-07-12 1997-01-17 Soc Et Et D Applic Tech Sedat INJECTION SYRINGE, IN PARTICULAR LIQUID MEDICAL PRODUCTS, WITH MOBILE NEEDLE PROTECTOR
FR2741268A1 (en) * 1995-11-21 1997-05-23 Turtaut Patrick Pre-filled syringe with protected needle of variable length

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445612B2 (en) 1996-12-31 2008-11-04 Société de Conseils de Recherches et d'Applications Scientifiques, S.A.S. Safety injection device for a liquid or semi-solid composition
JP2009045501A (en) * 1998-09-18 2009-03-05 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) Syringe for injecting pasty or semi-solid formulation
WO2002096488A1 (en) * 2001-04-10 2002-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Safety injection device for a liquid or semi-solid composition
AU2002317721B2 (en) * 2001-04-10 2005-03-10 Ipsen Pharma S.A.S. Safety injection device for a liquid or semi-solid composition
AU2002317721C1 (en) * 2001-04-10 2006-06-08 Ipsen Pharma S.A.S. Safety injection device for a liquid or semi-solid composition
JP2006297126A (en) * 2001-04-10 2006-11-02 Soc De Conseils De Recherches & D'applications Scientifiques Sas Safe injection device for liquid or semi-solid composition
CN1332721C (en) * 2001-04-10 2007-08-22 研究及应用科学协会股份有限公司 Safety injection device for liquid or semi-solid composition
JP4771957B2 (en) * 2003-11-03 2011-09-14 ベクトン・ディキンソン・アンド・カンパニー Safety device for syringe

Also Published As

Publication number Publication date
EP0954346B1 (en) 2004-11-03
US6213983B1 (en) 2001-04-10
EP0954346A1 (en) 1999-11-10
ES2230628T3 (en) 2005-05-01
DK0954346T3 (en) 2005-01-31
PT954346E (en) 2005-02-28
ATE281198T1 (en) 2004-11-15
US5776107A (en) 1998-07-07
DE69731482T2 (en) 2006-05-04
HK1024190A1 (en) 2000-10-05
DE69731482D1 (en) 2004-12-09
AU5763598A (en) 1998-07-31

Similar Documents

Publication Publication Date Title
US5776107A (en) Injection device
JP2006297126A (en) Safe injection device for liquid or semi-solid composition
US20190282763A1 (en) Devices, systems and methods for medicament delivery
US7713244B1 (en) Syringes for administering pasty or semi-solid formulations
US10737030B2 (en) Fluid delivery device and method
US20090204102A1 (en) Intradermal syringe and needle assembly
AU2002317721A1 (en) Safety injection device for a liquid or semi-solid composition
US20130018326A1 (en) Medical fluid injection device and system
EP1786494A2 (en) Compression bulb hypodermic syringe
WO2014177160A1 (en) An injection device
US4816021A (en) Self-destructing hypodermic syringes and hypodermic plunger devices
RU2580196C2 (en) Blood sampling safety syringe with automatically retractable needle
US7445612B2 (en) Safety injection device for a liquid or semi-solid composition
JP2004527335A (en) In particular, a mechanism to prevent premature activation during drug administration
AU2007203528A1 (en) Safety injection device for a liquid or semi-solid composition
JP2021528133A (en) Pharmaceutical product preparation devices and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997953913

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997953913

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997953913

Country of ref document: EP